

Proclamation 7207 of July 1, 1999

To Extend Nondiscriminatory Treatment (Normal Trade Relations Treatment) to Products of Mongolia and To Implement an Agreement To Eliminate Tariffs on Certain Pharmaceuticals and Chemical Intermediates

*By the President of the United States of America
A Proclamation*

1. The United States has had in effect a bilateral Agreement on Trade Relations with Mongolia since 1991 and has provided normal trade relations treatment to the products of Mongolia since that time. I have found Mongolia to be in full compliance with the freedom of emigration requirements of title IV of the Trade Act of 1974 (the "Trade Act") (19 U.S.C. 2432).
2. Pursuant to section 2424(b)(1) of Public Law 106-36, and having due regard for the findings of the Congress in section 2424(a) of said Law, I hereby determine that title IV of the Trade Act (19 U.S.C. 2431-2441) should no longer apply to Mongolia.
3. On November 13, 1998, members of the World Trade Organization (WTO), including the United States and 21 other major trading countries, announced in the WTO an agreement to eliminate tariffs on certain pharmaceuticals and chemical intermediates that were the subject of reciprocal duty elimination negotiations during the Uruguay Round of Multilateral Trade Negotiations (the "Uruguay Round"). A similar agreement between the United States and 16 other major trading countries eliminating tariffs on enumerated pharmaceuticals and chemical intermediates was implemented for the United States on April 1, 1997, by Proclamation 6982, adding such goods to the scope of the agreement on pharmaceutical products reached at the conclusion of the Uruguay Round and reflected in Schedule XX—United States of America, annexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade (1994) (Schedule XX).
4. Section 111(b) of the Uruguay Round Agreements Act (URAA) (19 U.S.C. 3521(b)) authorizes the President to proclaim the modification of any duty or staged rate reduction of any duty set forth in Schedule XX for products that were the subject of reciprocal duty elimination negotiations during the Uruguay Round, if the United States agrees to such action in a multilateral negotiation under the auspices of the WTO, and after compliance with the consultation and layover requirements of section 115 of the URAA (19 U.S.C. 3524). Section 111(b) also authorizes the President to proclaim such modifications as are necessary to reflect such duty treatment in Schedule XX by means of rectifications thereof.
5. On April 29, 1999, pursuant to section 115 of the URAA, the United States Trade Representative (USTR) submitted a report to the Committee on Ways and Means of the House of Representatives and the Committee on Finance of the Senate ("the Committees") that sets forth the proposed tariff eliminations, together with the advice received from the appropriate private sector advisory committee and the United States International Trade Commission regarding the proposed tariff

eliminations. During the 60-day period thereafter, the USTR consulted with the Committees on the proposed actions.

6. Section 604 of the Trade Act, as amended (19 U.S.C. 2483), authorizes the President to embody in the Harmonized Tariff Schedule of the United States (HTS) the substance of the relevant provisions of that Act, and of other acts affecting import treatment, and actions thereunder, including the removal, modification, continuance, or imposition of any rate of duty or other import restriction.

7. Pursuant to section 111(b) of the URAA, I have determined that Schedule XX should be modified to reflect the implementation by the United States of the multilateral agreement on certain pharmaceuticals and chemical intermediates negotiated under the auspices of the WTO. In addition, I have determined that the pharmaceuticals appendix to the HTS should be modified to reflect the duty eliminations provided in such agreement, and to make certain minor technical corrections in the identification of particular products in order to ensure that products are accorded the intended duty treatment.

NOW, THEREFORE, I, WILLIAM J. CLINTON, President of the United States of America, acting under the authority vested in me by the Constitution and the laws of the United States, including but not limited to section 2424(b)(2) of Public Law 106-36, section 111(b) of the URAA, and section 604 of the Trade Act, do hereby proclaim that:

(1) Nondiscriminatory treatment (normal trade relations treatment) shall be extended to the products of Mongolia, which shall no longer be subject to title IV of the Trade Act.

(2) The extension of nondiscriminatory treatment to the products of Mongolia shall be effective as of the date of signature of this proclamation.

(3) In order to implement the multilateral agreement negotiated under the auspices of the WTO to eliminate tariffs on certain pharmaceutical products and chemical intermediates, and to make technical corrections in the tariff treatment accorded to such products, the HTS is modified as set forth in the Annex to this proclamation.

(4) Such modifications to the HTS shall be effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after the dates set forth in the Annex for the respective actions taken.

(5) Any provisions of previous proclamations and Executive orders that are inconsistent with the actions taken in this proclamation are superseded to the extent of such inconsistency.

IN WITNESS WHEREOF, I have hereunto set my hand this first day of July, in the year of our Lord nineteen hundred and ninety-nine, and of the Independence of the United States of America the two hundred and twenty-third.

WILLIAM J. CLINTON

ANNEX

MODIFICATIONS TO THE HARMONIZED TARIFF SCHEDULE OF THE UNITED STATES

The Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, effective on the dates set forth for each annex section.

Section A. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after July 1, 1999, the following products are to be accorded duty-free treatment:

1. For subheadings 2905.22.50, 2910.30.00, 2921.43.40, 2922.19.20, 2924.29.05, and 2933.39.20, the Rates of Duty I—Special subcolumn is modified by inserting, in alphabetical order, the symbol “K” in the parentheses following the “Free” rate of duty in such subcolumn for each such subheading.

2. The Pharmaceutical Appendix to the HTS is modified as provided below:

(a) Table 1 of the Appendix is modified by adding the following new INNs, in alphabetical order, in the “Product” column and their CAS numbers in the “CAS No.” column:

Product	CAS Number	Product	CAS Number
abacavir	136470-78-5	eperezolid	165800-04-4
abefungin	122639-48-9	eperezimone	107724-20-9
abiraterone	153528-38-5	ertiprenotide	148031-34-9
abiraterone	154228-19-3	fabesetron	129300-27-2
acezozast	123548-56-1	fandofoxacin	164150-99-6
agomelatine	138112-76-2	faralimomab	167816-91-3
alirofloxacin	157182-32-6	fasidotil	135068-37-2
almetasetron	154541-73-7	fazaracetam	119295-15-5
almetasetron	154541-74-8	felvinimab	167747-20-8
amifutamide	61136-12-7	fexofenadine	83799-24-0
amikometasone	123013-22-9	fidarestat	136087-85-9
amitriptile	122384-88-7	filanastat	141194-34-1
apadoline	135003-30-4	filbanserin	167933-07-5
aztreonamab	154722-12-9	folitropin beta	150490-84-9
aztreonamab	155145-07-8	folivirsen	144245-52-3
aztreonamab	155242-02-5	forasartan	145216-43-9
aztreonamab	155205-48-0	forapitant	136468-36-5
aztreonamab	155218-47-3	fravietriptan	158747-02-5
aztreonamab	155220-35-5	fudostatine	13189-98-5
aztreonamab	155221-17-0	fulvestrant	129453-61-8
aztreonamab	155228-30-2	furamone	142996-66-5
aztreonamab	155262-71-3	gacyclidine	68134-81-6
aztreonamab	155307-46-1	ganaxolone	38338-32-2
bricodar	155997-04-1	gatifloxacin	160738-17-8
blomenasein	132810-10-7	gavestinel	153436-22-7
brimeltegravir	155122-66-5	glatipimod	134143-28-5
brimeltegravir	155778-82-7	glutefosamide	132682-98-5
brimeltegravir	179045-06-5	hemoglobin crosfumaril	142261-03-8
becaplermin	165101-51-9	hustumoren	159634-47-6
bedumomab	158318-83-9	icopezil	145508-78-7
bevirimedrone	158320-06-0	igovimab	171656-50-1
bevirimedrone	158326-30-2	indinavir	150378-17-9
bevirimedrone	158502-71-3	indisitron	141549-75-9
bevirimedrone	158502-73-3	infliximab	170277-31-3
bevirimedrone	158509-00-2	insulin aspart	116094-23-6
bevirimedrone	158509-02-2	insulin glargine	160337-95-1
bevirimedrone	158509-04-2	interferon alfacon-1	118390-30-0
bevirimedrone	158509-06-2	isocandilic acid (123 I)	74835-17-7
bevirimedrone	158509-08-2	isoflupane (123 I)	157596-07-3
bevirimedrone	158509-10-2	isoprotone (123 I)	160738-17-8
bevirimedrone	158509-12-2	ipamorelin	170651-70-4
bevirimedrone	158509-14-2	iroplact	154245-96-1
bevirimedrone	158509-16-2	israpafent	112779-73-9
bevirimedrone	158509-18-2	ivabradine	155974-00-8
bevirimedrone	158509-20-2	kelizimab	174722-30-6
bevirimedrone	158509-22-2	lagatide	157476-77-2
bevirimedrone	158509-24-2	lanolol	133242-30-5
bevirimedrone	158509-26-2	lamepitant	170566-84-4
bevirimedrone	158509-28-2	lansinavir	175385-62-3
bevirimedrone	158509-30-2	leodoxantrone	113457-05-9
bevirimedrone	158509-32-2	lefradilbans	149503-79-7
bevirimedrone	158509-34-2	levocetirizine	130018-77-8
bevirimedrone	158509-36-2	levosalbutamol	34391-04-3
bevirimedrone	158509-38-2	licosind	153394-81-5
bevirimedrone	158509-40-2	linazolidine	159776-68-8
bevirimedrone	158509-42-2	linazolid	163800-03-3
bevirimedrone	158509-44-2	linipiril	136320-85-6
bevirimedrone	158509-46-2	linutromab	160895-32-3
bevirimedrone	158509-48-2	lirexapride	145414-12-6
bevirimedrone	158509-50-2	lodenosine	110143-10-7
bevirimedrone	158509-52-2	lotrafiban	770495-14-2
bevirimedrone	158509-54-2	lumefintarne	82186-77-4
bevirimedrone	158509-56-2	luteolin	149882-10-0
bevirimedrone	158509-58-2	maxokalin	164178-54-5
bevirimedrone	158509-60-2	melagatran	159776-70-2
bevirimedrone	158509-62-2	mecladrine	134865-33-1
bevirimedrone	158509-64-2	mesipiperone (11 C)	94153-50-1
bevirimedrone	158509-66-2	metesind	138384-68-6
bevirimedrone	158509-68-2	milacainide	141725-10-2
bevirimedrone	158509-70-2	milameeline	139886-32-1
enacalide	169802-84-0		
enlimomab pegol	155773-59-4		

Annex (con.)

-2-

Section A (con.)
2. (con.)
(a). (con.)

Product	CAS Number	Product	CAS Number
milfusartan	148564-47-0	ritonavir	152213-67-5
milodistim	137463-76-4	rituximab	174722-31-7
minalrestat	129688-50-2	rivastigmine	123441-03-2
minodronic acid	127657-42-5	rizatriptan	144034-80-0
miproxifene	129612-87-9	robalzotan	169758-66-1
mitiglinide	145375-43-5	roflumilast	162401-32-3
minobulin	122332-18-7	rosiglitazone	122320-73-4
moxifloxacin	151096-09-2	roxifiban	170902-47-3
moxilubant	146978-48-5	rupatadine	158876-82-5
nagrestipen	166089-33-4	sabcomeline	159912-33-5
nateglinide	105816-04-4	samarium (153 Sm) lexidronam	154427-83-3
nelfinavir	159901-77-7	sampatrilat	120201-38-2
neizantrazole	121032-29-9	sarecycline	142001-63-6
neopulant	183747-35-5	scopinast	145574-90-9
neprafenac	78281-72-8	seocalcitol	134404-52-7
neprazole	156601-79-5	sevelamer	52757-95-6
nepicastat	173997-05-2	sibrafiban	172927-65-0
nerelimab	162774-06-3	sildenafil	139755-83-2
nifekalant	130636-43-0	silperstone	140944-31-6
nolatrexed	147149-76-6	sinapulitide	138531-07-4
nolpitantum besilate	155418-06-7	sinatrodil	143248-63-9
nonacog alfa	113478-33-4	spipatrigine	130800-90-7
oberadillo	114856-44-9	stafloxacin	127254-12-0
omapatrilat	167305-00-2	sivelestat	127373-66-4
omifloxacin	176891-05-0	soretilide	131003-08-6
opanixil	152539-19-9	sulesomab	167747-19-2
opratromum iodide	145919-78-0	sunegrapan	148408-54-5
oprelvekin	145941-26-0	talirelin	103300-74-9
orazipone	137109-78-5	taliravilane	169312-27-0
orbofibran	163250-90-6	targinine	17035-90-4
osanetant	160492-56-8	tasonermin	94948-59-1
osutidine	140695-21-2	tazomelina	131987-54-7
pagoclone	133737-32-3	technetium (99m Tc) nofetumomab	
palinavir	154612-39-2	merpenant	165942-79-0
palonosetron	135729-56-5	technetium (99m Tc) pintumomab	157476-76-1
pamaquaside	150332-35-7	technetium (99mTc) apcitide	178559-14-3
pamitrapase	151912-42-4	temeverine	173324-94-2
paricalitol	131918-61-1	temocaprilat	110221-53-9
peguinstudin	186332-88-8	terbogrel	149650-74-8
pedesine	133432-71-0	tereratigmine	147650-50-8
petubifolin	69956-77-0	ticagrelor	154413-61-3
penetrorexed	137281-23-3	tifacogin	148883-56-1
perifosine	157716-52-4	tilnoprofen arbamol	159098-79-0
peixiganan	172820-21-4	tivapipine	137332-54-8
pibutidine	103922-33-4	tobicillin	151287-22-8
pifonakin	112721-39-8	tramerin	131094-16-1
pileonaril	153168-05-9	trastuzumab	180288-69-1
pralmorelin	158861-67-7	trecoxibone	148998-94-1
pramlintide	151126-32-8	tresperimus	160677-67-8
pranazeptide	150408-73-4	upenazime	95268-62-5
pregabalin	148553-50-8	urokinase alfa	99821-47-3
prucalopride	179474-11-8	valganciclovir	175865-60-8
prumprazole	158620-59-1	valinomycin	101319-92-2
quiescine	111974-69-7	valsopdar	121284-77-7
quilostigmine	139314-01-5	vatamidipine	116308-55-5
raltitrexed	112887-68-0	vedascidine	141575-50-0
ranelic acid	135459-90-4	vinflunine	162652-95-1
rapacuronium bromide	156137-99-4	xaliproden	135354-02-8
resocortol	76675-97-3	xemilofibran	149820-74-6
retigabine	150812-12-7	ziconotide	107452-89-1
revatropate	149926-91-0	zinostatin stimalamer	123760-07-6
rifalazil	129791-92-0	zolmitriptan	139264-17-8
rismorelin	146706-68-5		

(b). Table 2 of the Appendix is modified by adding the following chemical or INN derivative names in alphabetical order:

*BENZOATE
DIFUMARATE
DIPIVOXILMONOBENZOATE
TETRAISOPROPYL*

(c). Table 3 of the Appendix is modified by adding the following product names, in alphabetical order, along with their CAS numbers:

Product	CAS Number
*(S)-but-3-yn-2-ol	2914-69-4
2-(4-fluorobenzyl)thiophene	63877-96-3
5-amino-N,N-bis(2-acetoxy-1-(acetoxymethyl)ethyl)-2,4,6-triiodoisophthalimide	148051-08-5
5-amino-N,N-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalimide	76801-93-9
(S)-but-3-enyl-2-methoxyethyl acetate	38533-95-2
diethyl diglycosidomalonate	6065-62-0
5-methyl-N-(4-(sulfonyl)phenethyl)pyrazine-2-carboxamide	33286-71-0
(5aR,11bS)-9,10-dimethoxy-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[1,2-c]-quinaline hydrochloride	178357-37-4
methoxy-1-(propanoylcarbamoyl)-L-valinate	151284-77-7
(4-4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-4H-[1,3]thiazolo[3,2-a]quinoine-3-carboxylic acid	12864-69-8
methyl 3-amino-4,6-dibromo-o-toluate	119915-25-1
4,6-dibromo-3-fluoro-o-tolue	119915-27-7
7-bromo-1-cyclopropyl-6-fluoro-5-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid	119915-34-6

Annex (con.)

-3-

Section A. (con.)
(c. (con.)

Product	CAS Number
2-mercapto-5-(trifluoromethyl)anilinium chloride	4274-38-8
2-(3-bromophenoxy)tetrahydropyran	57999-49-2
6-chloro-5-(2-chloroethyl)indol-2(3H)-one	116289-55-7
6-chlorindol-2(3H)-one	56200-19-2
6-ethoxy-2-(2,3-dihydro-1-naphthone	1078-19-9
M-[N-(tert-butoxycarbonyl)-L-alanyl]-L-alanine hydrate	90303-36-9
2,2-dithiobenzonitrile	33174-74-2
2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoic acid	194602-23-8
1-methyl-4-niro-3-propylpyrazole-5-carboxamide	138758-37-7
(S)-2-(4-fluorophenyl)-2-methylpropanoic acid	5332-31-1
6-(benzimidazol-2-yl)propanoic acid	64137-52-6
7-chloro-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one	2886-65-9
2-bromo-4-chloro-2-(2-fluorobenzoyl)acetanilide	1584-62-9
2-benzoyl-2-bromo-4-chloroacetanilide	41526-21-0
(RS)-acrinhydride hydrochloride	58519-11-1
2,3-dihydro-1,4-dihydro-2H-pyridine	21408-03-3
dimethyl chloromannide	28868-76-0
4,6-dichloro-5-(2-methoxyphenoxy)-2,2-bipyrilimidinyl	150728-13-5
4-tert-butylbenzenesulfonamide	6292-59-7
methyl 3-(methoxycarbonylmethyl)sulfamoylthiophene-2-carboxylate	106820-63-7
methoxy-4-(hydroxymethylsulfonyl)indol-2(3H)-one	56200-00-0
tert-butyl 3-(6,6-dioxo-6,6-dihydro-2H-1,2-diazepin-1-carboxylate	106928-72-7
ethyl (R)-2-hydroxy-4-phenylbutyrate	90315-82-5
1-benzyl-5-(4-phthalimidoglutamate	88784-33-2
(S)-1-(benzylxycarbonyl)hexahydroimidazepine-3-carboxylic acid	65632-62-4
methyl [(1S,2R)-1-benzy-3-(3S,4S,8S)-3-(tert-butylcarbamoyl)decahydro-2-(2S)-2-hydroxypropanoate	178680-13-2
(3S,4S,8S)-3-(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-3-tert-butyldecahydroisoquinoline-3-carboxamide	
136522-17-3	
4-(S)-3-amino-2-oxypyrimidin-1-ylbenzonitrile hydrochloride	175873-06-2
ethyl 3-[3-(S)-1,4-(N ₂ -hydroxyimino)phenyl]-2-oxypyrimidin-3-yl]ureido]propionate	175873-19-5
4-(2-oxo-2-oxazolidinyl)-1,3-dihydro-2H-1,2-diazepin-1-carboxamide	168200-42-5
4-hydrazonobenzenesulfonamide hydrochloride	17852-52-7
4-amidinoacuinalinic acid hydrochloride	149177-92-4
ethyl (S)-3-amino-4-ynoate hydrochloride	154772-45-9
11-alpha-hydroxy-11-alpha-(methoxycarbonyl)-o-pro pregn-4-ene-21,17-alpha-carbolactone	192704-56-8
11-alpha-hydroxy-11-alpha-(3-oxo-3-ynoate)-21,17-alpha-carbolactone	17342-54-4
4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide	181865-72-7
5-methyl-3-diphenyl-4-dihydroisoxazol-5-ol	181869-73-1
N-(4-(5-methyl-3-phenylisoxazol-4-yl)phenylsulfonyl)propionamide, sodium salt	198470-85-6
5-(4-(5-methyl-3-phenylisoxazol-4-yl)phenylsulfonyl)propionamide, sodium salt	105889-80-3
benzhydryl 5-(4-methylbenzamido)penicillanic acid 4-oxide	77887-68-4
benzhydryl 7-(2,2,2-[tert-butoxycarbonyl]amino)thiazol-4-yl]-4-(3-methylbut-2-enoxy carbonyl)but-2-enamido	174761-17-2
N-(2-quinolycarbonyl)-L-asparagine	136485-98-0
methy N-(methoxycarbonyl)-L-alaninate	41845-71-7
N-(2-oxo-2-oxazolidinyl)-2-(2,6-trisopropylphenyl)acetamide	16185-11-1
(2S)-3-methyl-3-(3-oxo-2-2-dihydro-1,2-benzisothiazol-2-yl)valeric acid	177785-47-8
(1S,4R)-1-azabicyclo[2.2.2]octan-3-one O-(Z)-3-methoxyphenyl)ethoxyoxime-maleic acid (1:1)	180050-34-4
N-(R)-9-methyl-1-oxo-1-phenyl-3,4,6,7-tetrahydro-1,4-diazepin[5,7,1]h[1]isoindolinimide	179024-48-7
4-acetamido-2-aminobenzoic acid	112522-64-2
N,N-bis[3-(ethoxyamino)propyl]propane-1,3-diamine tetrahydrochloride	156888-85-0
ethyl 5-[2-(2-aminooxy)-2-oxo-2-oxazolidinyl]butanoate	20337-04-0
ethyl (3R)-3,4-dihydroxybutylthiophene-2-carboxylate	208337-83-1
ethyl 5-(3R)-3-hydroxybutylthiophene-2-carboxylate	208337-84-2
ethyl 5-(3R)-4-(tert-butoxycarbonyl)amino-3-hydroxybutylthiophene-2-carboxylate	186521-39-0
ethyl 5-(3R)-4-(tert-butoxycarbonyl)amino-3-(mesyloxy)butylthiophene-2-carboxylate	186521-39-1
ethyl 5-(3R)-4-(acetylthio)-4-(tert-butoxycarbonyl)amino-3-hydroxybutylthiophene-2-carboxylate	186521-40-4
diethyl (S)-3-(tert-butoxycarbonyl)aminoethyl-2-(5-thioxocarbonyl-2-thienyl)propylthio] malonate	186521-41-5
methy (S)-5-[2-(5-ethoxycarbonyl)-2-thienyl]ethyl-3-oxo-1,4-thiazinane-2-carboxylate	186521-42-6
ethyl (S)-5-[2-(2-aminooxy)-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b]1,4]thiazin-6-yl]ethylthiophene-2-carboxylate	186521-44-8
(S)-5-[2-(2-aminooxy)-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b]1,4]thiazin-6-yl]ethylthiophene-2-carboxylic acid	186521-45-9
diethyl N-[2-(S)-2-aminooxy-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b]1,4]thiazin-6-yl]-ethyl[2-(thienoyl)-L-glutamate	177575-19-8
4-chloropyridine hydrochloride	7379-35-3
4-phenoxy pyridine	4783-66-2
4-(4-pyridyloxy)benzenesulfonic acid	102230-67-7
4-(4-pyridyloxy)benzenesulfonil chloride hydrochloride	192330-46-7
(S)-2,2-dimethyl-1,4-thiazinane-3-carboxylic acid	84915-43-5
(S)-2,2-dimethyl-1-(4-(4-pyridyloxy)phenylsulfonyl)-1,4-thiazinane-3-carboxylic acid	192329-63-2
2-amino-5-bromo-6-methylquinolin-4-(1H)-one	147149-88-1
3-azoxo-5-tetrahydro-1H-1,2-dihydro-1,2-dioxole-4-carboxylic acid	168838-09-9
(4R,5R)-4-azoxo-5-oxymethyl-1,3,2-dioxathiolane 2,2-dioxide	205338-09-8
2R,3R-1,4-bis(2-oxymethyl)-1,6,10-trien-3-ol	1947-62-2
3,7,11-trimethyldeca-1,6,10-trien-3-ol	7212-44-4
(E,E,10E,14E)-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraeno-3-ol	1113-21-0
methyl 4-amino-5-nitro- <i>o</i> -anisate	59338-84-0
methyl 2-(ethoxyamino)-5-nitro- <i>o</i> -anisate	62140-57-4
methyl 2-(ethoxyamino)- <i>o</i> -anisate	33040-02-2
3-methoxy-5-sulfamoyl- <i>o</i> -anisic acid	66544-80-2
1-benzylpiperidine-4-carboxaldehyde	22065-85-6
(E)-3-[(ER,7R)-7-amino-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-an-3-yl]allyl]-carbamoylmethyl(ethoxy)ethylammonium	160115-08-2
(E)-3-[(ER,7R)-7-amino-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-an-3-yl]allyl]methanol	11175-13-3
(Z)-3-(5-amino-1,2,4-trifluorazol-3-yl)-2-(fluoromethoxy)iminoacetic acid	116833-10-4
2-ethylmethoxyiminoacetamide	116833-20-6
4-chloro-2-(Z)-(methoxycarbonyl)methoxyimino-3-oxobutyric acid	84080-70-6
2-(5-ethyl-2-pyridyl)ethanol	5223-06-3
2-(5-ethyl-2-pyridyl)ethoxy-2,5,7,8-tetramethyl-4-oxochroman-8-yl acetate	107198-37-4
chromone-4-carboxylic acid	18844-38-4
7-ethyl-3-(2,6-dimethylsulfonyl)oxyethylindole	185453-95-8
5-amino-2,4,5-trisubstitutedphthalic acid	35453-19-1
4-azido-2-oxo-2-oxazolidinyl	2520-11-1
thiazolidine-2,4-dione	2295-31-0
2-bromo-3-methylthiophene	14282-76-9
5-methyluracil	65-71-4

Annex (con.)

-4-

Section A. (con.)

2. (con.)

(c). (con.)

Product

CAS Number

thymidine	50-89-5
3-(cyanoimino)-3-piperidinopropionitrile	103577-66-8
N-acetyl-3-(3,4-dimethoxyphenyl)-DL-alanine	56488-00-7
2,5,7,8-tetramethyl-2-(4-nitrophenoxymethyl)-4-oxochroman-6-yl acetate	27313-65-1
methyl 4-(bromomethyl)-m-anisate	107188-34-7
9-bromo-4,5,5,5-tetrafluoropentyl sulfide	70264-94-7
2-(phenylthio)aniline	14718-55-5
4,4,5,5,5-pentafluoropentan-1-ol	1134-94-7
methyl (S)-2-amino-4-(1H-tetrazol-5-yl)butyrate	127105-49-1
(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amine	184475-15-2
5-hydroxy-1,2-dihydro-1,2-dihydro-1-naphthone	2833-83-2
(R)-3-(4-aminophenyl)-3-azopyrazine	15694-55-9
methyl 4-acetamido-o-anisate	4093-29-2
4-acetamido-5-chloro-o-anisic acid	24201-13-4
methyl (1S,2S)-1-benzyl-3-chloro-2-hydroxypropylcarbamate	176972-62-5
ethyl 4-chloronicotinate	148043-73-6
ethyl 4-chloronicotinate	49906-01-7
6-hydroxynicotinic acid	5006-55-6
6-chloronicotinic acid	5326-23-8
1-acetylpirazine	13889-98-0
8-azaspiro[4.5]decan-7-9-dione	9818-89-4
(S)-2-(4-(2,7-dimethyl-4-oxo-1-dihydroquinazolin-6-yl)methyl)[prop-2-ynyl]amino-	1075-89-4
2-(2-phenylbenzamido)-4-(1H-tetrazol-5-yl)butyric acid	153537-73-5
SC-59735	116633-33-6
SC-70933	193700-51-6
6,7-dichloro-2,3-dimethoxyquinolin-5-ylamine	178619-89-1
4-(2-methyl-1H-imidazol-4-yl)benzoic acid	132026-12-1
methoxy-4-(4-methoxyphenyl)benzoic acid hydrochloride	166943-39-1
2-chlorothiophenyl 4-nitrophenoxy ether	3363-72-0
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol-(1R,4S)-2-exobutane-10-sulfonic acid (1:1)	188416-34-4
6-ethyl-5-fluoropyrimidin-4(1H)-one	137234-87-8
diphenyl[(S)-propyl]-(3-(2-phenyl-2-hydroxypropyl)hydrobromide	194802-27-2
(2,3-dihydro-1H-1,2,4-triazol-3-yl)acetic acid	69999-16-2
cyclohexylammonium 1-(S)-2-(tert-butoxycarbonyl)-3-(2-methoxyethoxy)propyl-cyclopentanecarboxylate	167944-94-7
cis-4-(benzyloxycarbonyl)-cyclohexylammonium tosylate	67299-45-0
5-bromo-3-(R)-4-methoxy-2-vinylmethyliindole	143322-57-0
meso-3,4-dicyclohexyl-3-(2-methoxy-3-phenyl-1,2-dihydro-1,2-dihydro-1-naphthoquinolin-5-yl)amine	151862-71-9
distyryl-6-chloro-9H-carbazol-2-ylmethyliindole	71206-55-4
beta-cyclodextrin sulfobutyl ethers, sodium salts	182410-00-0
N-(2-chloroethyl)pyrrolidine hydrochloride	7250-67-1
6,7-bis(2-methoxyethoxy)quinazolin-4(1H)-one	179688-29-0
ethyl 3,4-dihydroxybenzoate	3519-53-3
5-(2-methoxyethoxy)-2-(2-methoxyethoxy)phenyl-2-phenylbut-1-enylphenol	8800-34-4
2-(1-tert-butoxycarbonyl)-4-piperidylacetic acid	157688-46-5
4-pyridylacetic acid hydrochloride	6622-91-9
a, a, a-trifluoro-4-nitro-m-toluidine	393-11-3
methyl 1,2,3,5-tetra-O-acetyl-beta-D-[beta]-D-[beta]-D-[beta]-D-[beta]-L-xylose	39925-10-5
Na-[tert-butylcarboxy]-(2-methoxy-N-methyl-Nw-nitro-L-argininamide	21-18-3
N-[tert-butylcarboxy]-(2-methoxy-N-methyl-Nw-nitro-L-argininamide	139976-34-4
(2S,3S)-3-amino-2-ethoxy-N-nitropiperazine-1-carboxamide hydrochloride	160250-77-6
(S)-O-benzylaldehyde-N-(tert-butoxycarbonyl)hydrazone	192802-28-1
phenyl (4-(4-(4-hydroxyphenyl)-)piperazin-1-yl)phenylcarbamate	184177-81-9
{(2S)-2-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl)methyl-4-chlorobutyl ester	175712-02-4
8-chloro-11-(4-piperidylidene)-5,6-dihydro-11H-benz[5,6]cyclohepta[1,2-b]pyridine	100643-71-6
2-hydroxy-2-methyl-4-nitro-(trifluoromethyl)propionanilide	52806-53-8
5-acetylsalicylamide	40187-51-7
8-chloro-5,6-dihydro-11H-benz[5,6]cyclohepta[1,2-b]pyridin-11-one	312511-19-9
1-methyl-2-(2,4-dichlorophenoxy)-2-methoxyethane	47-33-2
3-chloropropylideneammonium chloride	5407-04-5
3-(trichlorovinyl)aniline hydrochloride	81972-27-2
2-(1-mercaptopropyl)cyclopropylacetic acid	162515-68-6
3-(4-bromobenzyl)-2-buty-4-chloro-11H-1,2,4-triazol-5-ylmethanol	151015-31-6
4-chloro-2-methoxy-4-nitro-2,6-dimethylphenyl	5323-83-8
methoxy-2-(4-(E)-3-(2-(7-chloro-2-quinolyl)vinyl)phenyl)-3-hydroxypropylbenzoate	181136-72-0
methoxy-2-(4-(E)-3-(2-(7-chloro-2-quinolyl)vinyl)phenyl)-3-oxopropylbenzoate	149968-11-6
2-(2-trityl-2H-1,2,4-triazol-5-yl)phenylboronic acid	143722-25-2
(3S,8aR)-3-(2R,4S)-2-benzy-4S-epoxovaleryl-2,2-dimethyl-3,3a,8,8a-tetrahydro-2H-indenyl-1,2-dioxane	158512-24-4
N-(4S,8S)-5-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-ylacetamide	170886-83-7
N-(4S,8S)-5-methyl-7,7-dioxo-2-sulfamoyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-yl) acetamide	147200-03-1
5-iodouracil	696-07-1
N ¹ -methyl-1H-pyrazole-1-carboxamidine hydrochloride	59194-35-3
(S)-tetrahydrofuran-3-ol	68087-23-2
ethyl 4,6-dimethyl-2-methoxy-2-carboxylate	153430-70-0
3-oxoprop-1-ene-17-beta-carboxylic acid	302-97-6
alpha, alpha, alpha, alpha, alpha, alpha-hexafluoro-2,5-xylylne	328-93-8
(2,2-azebicyclo[2.2.1]hept-5-en-3-one	61885-46-3
(1R,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one	79200-56-9
(1S,4R)-4-(2-chloro-4-methyl-phenyl)-2-oxocyclopent-2-enyl)methanol hydrochloride	172015-19-7
4-(2-chloro-4-methyl-phenyl)-2-oxocyclopent-2-enyl)methanol	171881-03-9
4-fluorobenzyl 4-(methoxymethoxy)phenyl ketone	87483-29-2
2-amino-3-pyridyl methyl ketone	65326-33-2
6-methoxy-1H-purin-2-ylamine	20535-83-5
1-beta-D-arabinofuranosylpyrimidine-2,4(1H,3H)-dione	3083-77-0
(2R)-3-aminohex-2-(S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)valeric acid	157518-00-2
3-(4-aminophenyl)-2-methyl-1,2,3-triazeno[4,1-a]pyridine	171711-07-1
3-nitro-4-pyridone	5435-54-1
2,6-difluorobenzylamine	69385-30-4
L-ribose	24259-59-4
(5,6-dichloro-1H-benzimidazol-2-yl)isopropylamine	176181-55-0
(3S,4R,5R,8aR)-5,6-dichloro-2,2-dimethyl-3,3a,8,8a-tetrahydro-2H-1,2-dioxane	151851-75-7
3-(4-aminophenyl)cobutane-2-carbonitrile	15780-35-7
4-tert-butylbenzyl 2-(2R,4S)-3-(R)-1-(tert-butylidemethylsilyloxy)ethyl-2-((1R,3S)-3-methoxy-2-oxocyclohexyl)-4-oxoazetidin-1-yl)-2-oxoacetate	159593-17-8
methyl (3aR,4R,7aR)-2-methyl-4-(15aR)-1,2,3-triazeno[4,1-a]pyrid-3a,7a-dihydro-4H-pyran-4-oxo-5-carboxylate	78880-37-0
(4S,5R,5R)-5-sulfamido-4-amino-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydropyran-2-carboxylic acid	130525-62-1

Annex (con.)

-5-

Section A. (con.)

Annex (con.)

-6-

Section A. (con.)

Annex (con.)

-7-

Section A. (con.)
 2. (con.)
 (c). (con.)

Product

CAS Number

(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-ylmethanol	145514-04-1
(4R,5S,6S,7R)-1,3-bis(3-aminobenzyl)-4,7-dibenzyl-5,6-dihydroxyhexahydro-2H-1,3-diazepin-2-one dimethanesulfonate	177932-89-7

Section B. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after April 1, 1997, the following technical corrections are made to the enumerated subheading:

1. For subheading 2918.13.50, the Rates of Duty 1-Special subcolumn is modified by inserting, in alphabetical order, the symbol "K" in the parentheses following the "Free" rate of duty in such subcolumn.
2. The Pharmaceutical Appendix to the HTS is modified by adding to Table 3 of the Appendix the following product, with the product name inserted in alphabetical order in the "Product" column and its Chemical Abstracts Service (CAS) registry number in the "CAS No." column:

1-[N2-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyl]proline 103300-91-0

Section C. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after January 1, 1995, the following technical corrections are made to the enumerated subheadings:

For subheadings 2904.90.47, 2917.39.30, 2918.29.20, 2935.00.05, and 3402.20.10, the Rates of Duty 1-Special subcolumn is modified by inserting, in alphabetical order, the symbol "K" in the parentheses following the "Free" rate of duty in such subcolumn for each such subheading.

Proclamation 7208 of July 7, 1999

**To Facilitate Positive Adjustment to Competition From
 Imports of Lamb Meat**

*By the President of the United States of America
 A Proclamation*

1. On April 5, 1999, the United States International Trade Commission (USITC) transmitted to the President a unanimous affirmative determination in its investigation under section 202 of the Trade Act of 1974, as amended (the "Trade Act") (19 U.S.C. 2252), with respect to imports of fresh, chilled, or frozen lamb meat, provided for in heading 0204 of the Harmonized Tariff Schedule of the United States (HTS). Under section 202 of the Trade Act, the USITC determined that such lamb meat is being imported into the United States in such increased quantities as to be a substantial cause of the threat of serious injury to the domestic industry producing a like or directly competitive article. Further, the USITC, pursuant to section 311(a) of the North American Free Trade Agreement Implementation Act (the "NAFTA Implementation Act") (19 U.S.C. 3371(a)), made negative findings with respect to imports of lamb meat from Canada and Mexico. The USITC also transmitted to the President its recommendation made pursuant to section 202(e) of the Trade Act with respect to the action that would address the threat of serious injury to the domestic industry and be most effective in facilitating the efforts of the domestic industry to make a positive adjustment to import competition.